% 0期刊文章% Zuzana Nedelska %一个布拉德利Boeve克里斯托弗·施瓦兹% %斯科特Przybelski罗伯特·里德% %杰弗里·冈特%一个马太Senjem %格伦·史密斯%坦尼斯Ferman %一个David Knopman Yonas Geda % %一个罗纳德·彼得森% Clifford杰克% Kejal Kantarci % Tβ-amyloid负载对白质完整性的影响与路易体痴呆(P6.322) % D J神经病学2014% % P P6.322 % V 82% N 10补充% X目的:描述模式的白质(WM)扩散系数的变化与路易体痴呆(下文)使用扩散张量成像(DTI)分布分析,并评估的影响β-amyloid (Aβ)负载在下文WM完整性。首页背景:路易体痴呆患者,AD-type病态经常重叠在。下文患者具有广泛白质扩散系数对DTI的改变。广告病理学扩散系数变化的贡献下文亦尚不清楚。设计/方法:我们连续招募患者临床诊断可能下文(n = 30)和确定性别和年龄广告(n = 30)和认知正常控制(n = 60)科目,接受DTI C-11匹兹堡化合物B(加以宠物研究。全球皮质加以保留比蠅1.5被认为是加以+和< 1.5加以-。所有患者的广告都需要加以+和加以控制。下文患者分为加以+ (n = 14)和加以- (n = 16)组。差异分数各向异性(FA)在分段WM使用分布分析评估(VBA) SPM5 (p < 0.05;修正为多个比较)和parcellated到约翰霍普金斯大学(JHU)阿特拉斯roi群体间的比较使用Wilcoxon rank-sum测试。 RESULTS: Both DLB PiB+ and AD patients were characterized by decreased FA in the cingulum tract, occipital, parietal, and lingual WM compared to controls on VBA. We found no FA decreases in PiB- DLB patients compared to controls on VBA. However, we observed FA decreases in the occipital WM and FA increases in the cingulum tract in PiB- DLB patients compared to controls on JHU ROI analysis (p<0.05). CONCLUSIONS: Although high Aβ load on PET appears to disrupt the limbic and parietal WM integrity, disruption of occipital WM integrity is not dependent on Aβ in DLB. DTI may be a non-invasive diagnostic marker for AD-related pathology in patients with DLB for disease-specific treatments. Study Supported by: AG040042, AG11378, AG16574,AG06786, Mangurian Foundation, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer Disease Research ProgramDisclosure: Dr. Nedelska has nothing to disclose. Dr. Schwarz has nothing to disclose. Dr. Boeve has received research support from Cephalon, Inc., Allon Therapeutics, and GE Healthcare. Dr. Reid has nothing to disclose. Dr. Przybelski has nothing to disclose. Dr. Gunter has nothing to disclose. Dr. Senjem has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Ferman has nothing to disclose. Dr. Geda has nothing to disclose. Dr. Knopman has received personal compensation for activities with Eli Lilly & Company and TauRx Pharmaceuticals. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from Janssen and Baxter. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., and Janssen Alzheimer's Immunotherapy. Dr. Petersen has received royalty payments from Oxford University Press. Dr. Jack has received personal compensation for activities with Janssen, Eisai Inc., General Electric, Johnson & Johnson, and Eli Lilly & Co. Dr. Jack has received research support from Pfizer Inc., Allon, and Baxter. Dr. Kantarci has received research support from Pfizer Inc., Jannsen Alzheimer immunotherapy, and Takeda Global Research & Development Center.Thursday, May 1 2014, 7:30 am-11:00 am %U